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Abstract
Identifying oral cancer lesions associated with high risk of relapse and predicting clinical outcome remain challenging
questions in clinical practice. Genomic alterations may add prognostic information and indicate biological aggressiveness
thereby emphasizing the need for genome-wide profiling of oral cancers. High-resolution array comparative genomic
hybridization was performed to delineate the genomic alterations in clinically annotated primary gingivo-buccal complex
and tongue cancers (n=60). The specific genomic alterations so identified were evaluated for their potential clinical
relevance. Copy-number changes were observed on chromosomal arms with most frequent gains on 3q (60%), 5p (50%), 7p
(50%), 8q (73%), 11q13 (47%), 14q11.2 (47%), and 19p13.3 (58%) and losses on 3p14.2 (55%) and 8p (83%). Univariate
statistical analysis with correction for multiple testing revealed chromosomal gain of region 11q22.1–q22.2 and losses of
17p13.3 and 11q23–q25 to be associated with loco-regional recurrence (P=0.004, P=0.003, and P=0.0003) and shorter
survival (P=0.009, P=0.003, and P 0.0001) respectively. The gain of 11q22 and loss of 11q23-q25 were validated by
interphase fluorescent in situ hybridization (I-FISH). This study identifies a tractable number of genomic alterations with few
underlying genes that may potentially be utilized as biological markers for prognosis and treatment decisions in oral
cancers.
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Introduction
Oral squamous cell carcinoma (OSCC) is a major cause of
morbidity and mortality worldwide, accounting for more than
275,000 new cases and over 120,000 deaths every year [1].
Although there have been improvements in the therapeutic
modalities, OSCC-associated morbidity and mortality remain
high and have not changed in over three decades [2]. This lack of
improvement in survival indicates that tumor size, lymph node
involvement and stage, which are considered as markers of disease
aggressiveness, do not sufficiently account for the observed
variability in clinical outcomes [3]. Therefore, a comprehensive
understanding of the pathological mechanisms of OSCC is needed
to complement the existing paradigms in assessing disease
aggressiveness and prognosis.
Chromosomal abnormalities are a characteristic attribute of
cancer cells and they have been used to define specific disease
entities. The advent of genome-wide screening methods such as
comparative genomic hybridization (CGH), and, more recently,
array CGH (aCGH), have opened up new possibilities to catalogue
chromosomal aberrations at high resolution [4,5]. Many chromo-
somal aberrations that may harbor oncogenes or tumor suppressor
genes have emerged as predictive and prognostic markers for
tumors [5,6]. OSCC is reported to arise through the accumulation
of numerous specific chromosomal alterations [2]. Gains mapped
on chromosomal arms 3q, 6q, 8q, 9p, 9q, 11p, 11q, 14q, 17q, and
20q and losses mapped on 3p, 4q, 9p, and 18q have suggested
putative oncogenes and tumor suppressor genes associated with
oral cancer [7–15]. Molecular profiles of oral cancers vary
throughout the world and are influenced by both aetiological
factors and ethnicity, yet no conclusive studies have been reported
to date [16,17]. Most genome-wide studies on OSCC have been
carried out on various intra-oral sites that are associated with
different aetiological agents. Apart from tobacco and alcohol,
human papilloma virus (HPV) infection is a known risk factor for
OSCC. HPV-infected oropharyngeal tumors comprise a distinct
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genetic alterations and better prognosis [18–20].
Previous studies have revealed certain over- and under-
expressed genes in oral cancer. Based on the existing literature,
we compiled a list of genes associated with oral cancer, which may
be useful in identifying and functionally validating driver genes in
the underlying regions of alteration. To date, only one study has
examined the clinicopathological association of genomic alter-
ations in a small set of OSCC (n=8) [9]. Therefore, the present
study aims at delineating genome-wide copy number alterations
(CNAs) in oral cancer and to understand whether these genetic
alterations are associated with clinical characteristics and progno-
sis. The study focuses on advanced-stage cancers of the
gingivobuccal complex and tongue, which are associated with
tobacco use and were found to be unrelated to HPV infection. We
demonstrate the potential of high-resolution genome-wide aCGH
for calling chromosomal alterations and identifying genomic
lesions associated with high risk of relapse and decreased survival
time.
Materials and Methods
Tissue sample collection and tumor micro-dissection
The study was approved by the human ethics committee of the
Tata Memorial Hospital. Neo-primary tumor samples were
obtained from 60 patients undergoing surgery for oral cavity
cancers at the Head and Neck Unit and were collected from the
tumor tissue repository at Tata Memorial Centre, Mumbai.
Patients received neither radiation nor chemotherapy before the
surgery. The tumor content in the tissues was assessed on a
Hematoxylin and Eosin (H&E)-stained section independently by
two pathologists. Tissues with more than 70% tumor content were
processed for aCGH. Informed written consent was obtained from
all participants of the study.
DNA Isolation from tissues
DNA was extracted following a standard phenol/chloroform
protocol. DNA quantification was performed on Nanodrop-1000
spectrophotometer (NanoDrop Technologies, Wilmington, Dela-
ware) and the quality was assessed by electrophoresis on 0.8%
agarose gel. A pool of ethnicity and gender-matched normal DNA
was isolated from the peripheral blood lymphocytes of healthy
donors (n=10) which was used as reference for aCGH.
HPV Typing
HPV presence was determined by polymerase chain reaction
(PCR) using GP5+/6+ primers [21] following confirmation of
amplifiable DNA by Beta-Globin PCR [22]. SiHa DNA for
HPV16, HeLa DNA for HPV18 (positive controls), and C33A
DNA, SCC074 (negative controls) were included while performing
all PCR reactions.
Array CGH Hybridization
Whole-genome copy number profiling was performed on 105K
CGH oligonucleotide arrays (Agilent Technologies, Santa Clara,
CA) according to the manufacturer’s instructions. Briefly, 4.5 mg
of tumor and pooled gender-matched reference DNA were labeled
with fluorochromes Cy3 and Cy5, respectively. Labeled samples
were purified using the genomic DNA purification module
(Agilent Technologies), combined, mixed with human Cot-1
DNA, and denatured at 95uC (Oligo aCGH hybridization kit,
Agilent Technologies). The mixture was applied to microarrays
and hybridization was performed at 65uC for 40 hours. After
hybridization, the microarrays were washed with Oligo aCGH
wash buffer followed by drying of slides. After drying, the arrays
were scanned using an Agilent Scanner (Agilent Technologies),
and log2-intensities were extracted from raw microarray image
files using the Agilent feature extraction software version 9.0
(Agilent Technologies). The raw aCGH data have been submitted
to Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/
geo/) with accession number GSE23831.
Genome mapping and Human structural variation
Genomic coordinates were standardized to the NCBI build 36
(hg18) assembly of the human genome. Loci of structural and copy
number variants were obtained from the Database of Genomic
Variants (DGV) version 9 at The Centre for Applied Genomics
(TCAG, http://projects.tcag.ca/variation/) [23].
Data Analysis
Raw aCGH intensity values were normalized using the R
package snapCGH [24] and segmented with the circular binary
segmentation (CBS) algorithm [25]. Recurrent copy number
alterations (CNAs) were called using the RAE method [26]. This
algorithm identifies significantly recurring CNAs using a back-
ground model of genomic variability and computes an empirical
false discovery rate (q-value) for each candidate CNA. Within
CNAs, the RAE algorithm also identifies subintervals called ‘‘focal
regions’’ that were more common. Thresholds for losses/deletions
and gains/amplifications were set adaptively from the distribution
of segment heights obtained by the CBS algorithm [25]; the
thresholds for deletions and amplifications were more stringent
than for losses and gains. RAE distinguishes between a ‘‘gain’’ of at
least a single copy and an ‘‘amplification’’ by two or more copies.
Similarly, RAE defines a ‘‘loss’’ of a single copy and a homozygous
‘‘deletion’’ of both copies [26].
CNAs were considered significant, if their q-value was smaller
than 0.1. Recurrent CNAs were further distinguished from
known copy number variants (CNVs) present in DGV. For
survival analysis, Cox proportional hazards models were
calculated with corresponding p-values from the Wald test.
Relapse and death from disease were considered as events for
recurrence-free and disease-specific survival, respectively. Associ-
ations of CNAs with clinical parameters were tested with Fisher’s
exact test. All statistical computations were performed in R (www.
r-project.org).
Validation of array CGH results using Fluorescence In-situ
Hybridization (FISH)
Chromosome 11q alterations associated with recurrence-free
and disease-specific survival revealed by aCGH were confirmed by
interphase FISH (I-FISH) using a dual color procedure. The
probes were prepared by differentially labeling the region and
centromere-specific bacterial artificial chromosome (BAC) clones
obtained from the Children’s Hospital Oakland Research
Institute, BACPAC Resources Center. The specificity of all the
BAC clones was confirmed on metaphase target slides (Vysis, CA,
USA) before hybridizations. BAC clone RP11-135H8 was used as
centromere-specific probe for all FISH experiments on chromo-
some 11, and served as a hybridization control. The copy number
status of chromosomal regions 11q22.1-q22.2 and 11q24.1 was
determined by applying probes prepared from clones RP11-90M3
and RP11-696J13 respectively and comparing them with the
centromeric control. In addition, gain of 7p12 and amplification of
11q13 were validated using locus-specific BAC clones RP11-
339F13 and RP11-300I6, respectively. BAC clone RP11-745J15
was used as centromeric probe for chromosome 7. FISH images
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Zeiss, Germany) and analyzed using the ISIS imaging software
(Metasystems, Germany).
Comparison of the identified copy number alterations to
published data. Using Entrez PubMed, PubMedCentral, and
the Science Citation Index, we compiled a list of studies that
reported either gene expression changes or copy number changes
associated with oral cancer. We also did a focused search for
studies suggesting roles for microRNAs in oral cancer, as this has
been a topic of increasing interest recently. Wherever possible,
gene names were standardized to the name approved by the
HUGO Nomenclature Committee (www.genenames.org) as of
June 2010.
Results
Demographic and clinicopathological characteristics
Array CGH profiling was done for 60 OSCC patient samples.
All patients in the cohort were tobacco habitue ´s and were found
to be HPV-negative (Table 1, Figure S1). The mean age of the
study cohort was 53 years (range, 31–80 years) with a higher
proportion of males (80%). Tumors were predominantly
moderately differentiated (60%) and were of locally advanced
stages III and IV (92%). The cohort had equal representation of
node-positive and node-negative groups. The median follow-up
period of patients was 22.7 months. Detailed demographic and
clinicopathological data of the study cohort is represented in
Table S1.
Genomic Aberrations
RAE analysis was performed to identify recurring disease-
associated chromosomal aberrations and segregate them from
neutral ones. At a false discovery rate of q=0.1, a total of 93
distinct CNAs were found by the RAE algorithm (Figure 1;
Figure S2), seven of which in the centromeric regions; for 13
CNAs an additional localized peak region was detected (Table
S2). Non-centromeric chromosomal aberrations occurring in
more than 20% of the cases are presented in Tables 2 and 3. A
large fraction of samples show gross whole chromosome-level
alterations (Figure 1). Overall, the number of chromosomal
losses (n=61, including 7 centromeric) was higher than the
number of gains (n=32), but the difference was smaller for high-
frequency CNAs (n=35 versus n=30). The detailed list of
‘‘candidate genes’’ for all the regions found altered is presented
in Table S2.
Copy number losses
The most frequently occurring losses were identified on
chromosomal regions 3p (62%), 5q (37%), 8p (83%), 9p (28%),
10p (35%), 11q (20%), 13p13 (32%), 18q (30%), and 19p12 (13%)
as represented in Table S2. Focal regions of loss included 1q24.2
(harboring the candidate gene NME7), 2q21.2 (NCKAP5), 3p14.2
(PTPRG), 3p25.2–p26.3 (CHL1, GRM7, RAD18, SRGAP3), 4q35.2
(MTNR1A, FAT1), 6p21.3 (HLA-DRA, HLA-DRB5, HLA-DRB6,
HLA-DRB1), 8p23.1 (CSMD1), 8p11.2 (ADAM5P, ADAM3A), 9p21
(MTAP, C9orf53, CDKN2A, CDKN2BAS, CDKN2B) 9p23-p24.3
(PTPRD), 17p13.3 (RPH3AL, MGC70870), and 22q13.1 (APO-
BEC3A, APOBEC3B) and is presented in Table S2. The previously
unreported focal loss of 9p23-p24.1 (PTPRD) in oral cancer is
shown in Figure 2.
Copy number gains
The most frequent aberrations included gain of chromosomal
regions 3q (60%), 5p (50%), 7p (50%), 8q (73%), 9q (40%), 11q13
(47%), 14q (38%), 19p13.3 (58%) and 20q (40%) as represented in
Table 3. Focal regions of amplification included 1q31.3 (CFHR3,
CFHR1) 2q37.3 (LOC728323) 3q27.1 (ABCC5, ALG3, EIF4G1,
EPHB3), 5p15.33 (PDCD6), 14q11.2, and 19p13.3 (KIR2 cluster,
PPAP2C, MIER2) as presented in Table S2.
Table 1. Clinicopathological characteristics of sixty oral
cancer patients.
Characteristics No. of patients (%)
Gender
Male 48 (80.0)
Female 12 (20.0)
Mean Age 53 (range 31–80)
Tumor sites
GBC* 53 (88.3)
Tongue 7 (11.7)
Habit Profile
Exclusive chewers 44 (73.3)
Exclusive smokers 2 (3.3)
Exclusive drinkers 0 (0.0)
Mix habitue ´s
{ 14 (23.3)
Pathological Grade
Well 2 (3.3)
Moderate 36 (60.0)
Poor 22 (36.7)
Pathological Cervical Lymph Node
involvement
Negative (N0) 30 (50.0)
Positive (N+) 30 (50.0)
Pathological Stage
I & II 5 (8.3)
III & IV 55 (91.7)
Treatment
Surgery only 6 (10.0)
Surgery + RT
{ 43 (71.7)
Surgery + RT
{+ CT
1 11 (18.3)
Recurrence Status
No recurrence 26 (43.3)
Recurrence 25 (41.7)
Lost to follow-up
#/unknown 9 (15.0)
Clinical outcome
Alive with no evidence of disease 25 (41.7)
Dead of disease 22 (36.7)
Alive with disease 3 (5.0)
Dead of other cause 1 (1.7)
Lost to follow-up
#/unknown 9 (15.0)
*GBC: Gingivobuccal complex;
{Mix habitue ´s: Patients with at least two of the habits smoking, chewing, and
drinking;
{RT: Radiation Therapy;
1CT: Chemotherapy;
#Lost to follow-up: Patients who did not attend the clinical check-up sessions
after primary treatment and as a result their clinical status (recurrence and
survival) could not be ascertained.
doi:10.1371/journal.pone.0017250.t001
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aberrations
Chromosomal aberrations were analyzed to understand their
relevance and associations with clinicopathological parameters
like nodal status, grade and clinical outcome. We did not find
any significant association of chromosomal aberrations with
nodal status or grade. Using the Cox proportional hazards
model, we find, at a corrected p-value ,0.1, n=11 CNAs
associated with recurrence-free and n=12 alterations associated
with disease-specific survival (Table 4). Whereas the gains of
chromosomal regions 11q12.2-q14.1 (P=0.06) and 11q22.1–
q22.2 (P=0.009) were associated with poor clinical outcome,
gain of 19p13.3 (P=0.04) was associated with better survival.
Chromosomal losses of 3p25.3–p26.3 (P=0.08), 6p25.3
(P=0.07), 17p13.3 (P=0.003), 11q23–q25 (P=0.0001) and
18p11.1-p11.21 (P=0.04) were associated with poor clinical
outcome, while loss of 4q13.2 (P=0.05) was associated with
better survival (Table 4).
Figure 1. Radial heatmap of recurring copy-number alterations (CNAs) in OSCC. Shown in the inner heatmap are copy number gains/
amplifications (blue) and losses/deletions (red), where tumors are stacked radially. Significantly recurring alterations (RAE q-value ,0.1) are displayed
between the outermost chromosome ideograms and the inner heat map (red: losses, blue: gains). Open circles denote known copy-number variants
(CNVs) that span more than 50% with recurring CNAs. Chromosome numbers are shown in bold at periphery of chromosome ideograms with
genomic coordinates in megabases.
doi:10.1371/journal.pone.0017250.g001
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(P=0.009) were found as the strongest predictors of poor clinical
outcome in terms of recurrence and survival (Table 4). Kaplan-
Meier survival curves for loss of distal 11q and gain of 11q22.1-
q22.2 are shown in Figures 3A and 4A. The chromosomal
interval 11q23–q25 was subdivided by RAE into four non-
overlapping intervals. The p-values for the four association tests
were almost identical, but the subdivision suggests that there were
multiple pertinent genes on 11q23–q25, at least one gene per
subinterval.
Fluorescence in situ hybridization (FISH) analysis
Array CGH results were validated using I-FISH analysis. The
samples were selected randomly from the cohort of 60 samples
with known array CGH-based copy number alterations. The
centromere- (RP11-135H8) and region-specific (RP11-90M3,
RP11-696J13) probes hybridized to their target loci showed no
cross reactivity (Figure S3). We validated loss of 11q23-q25
(Figure 3B and 3C) and gain of 11q22.1-q22.2 (Figure 4B and 4C)
associated with poor clinical outcome and found a concurrence of
70% and 82% respectively with array CGH data. In addition we
Table 2. Genome-wide alterations in OSCC: Losses & Deletions.
Cytoband Position Size (Mba) q value % Frequency
Start End Losses Deletions
1q11.1-q21.1 120982663 144003083 23.02 8.00E-06 30 5
1p36.33-p11.1 147134204 147499075 0.36 0.000231 23.3 5
1q24.2 167493797 167507911 0.01 0.00029 21.7 13.3
1q44 246713386 246852155 0.14 0.023854 20 10
2q21.2 133504494 133812256 0.31 8.00E-06 25 13.3
3p26.3-p25.3 39095 9150490 9.11 8.00E-06 45 0
3p14.2 60331268 61710321 1.38 8.00E-06 55 18.3
3p26.3-p11.2 39095 95021186 94.98 8.00E-06 61.7 25
3q26.3 163941201 164138371 0.2 8.00E-06 35 30
4q13.2 68901239 69688431 0.79 8.00E-06 43.3 30
4q13.3 70188483 70296201 0.11 8.00E-06 33.3 25
4q35.2 187570439 188216746 0.65 0.026337 20 0
4q35.2 190706301 191176358 0.47 0.000458 25 1.7
5q11.1-q14.3 49759749 88018996 38.26 8.00E-06 36.7 13.3
6p21.34 29962878 29981959 0.02 8.00E-06 26.7 23.3
6p21.33 29962878 29981959 0.02 8.00E-06 26.7 23.3
6p21.32 32605329 32633715 0.03 8.00E-06 43.3 43.3
6p21.32 32519964 32673012 0.15 8.00E-06 43.3 43.3
8p23.2 3400925 4000623 0.6 8.00E-06 65 25
8p11.23 39378080 39464606 0.09 8.00E-06 68.3 36.7
8p23.3-p11.1 63832 47740040 47.68 8.00E-06 83.3 65
9p24.1-p23 8924024 10013871 1.09 2.32E-05 23.3 6.7
9p21.3 21733439 22076827 0.34 8.00E-06 28.3 10
9p13.1-q21.11 38612224 70225195 31.61 8.00E-06 36.7 6.7
10p15.3-p11.1 138235 42150788 42.01 8.00E-06 35 10
10p11.21 37475290 37508431 0.03 8.00E-06 26.7 3.3
10q11.22 46396192 46516611 0.12 2.83E-05 25 5
11q22.3-q23.1 102611683 110151240 7.54 0.018658 20 0
11q23.3-q25 119044645 133316524 14.27 0.0113 20 0
13p13 6365 44752 0.04 8.00E-06 31.7 23.3
15q11.2 18741744 19805989 1.06 2.83E-05 23.3 8.3
18q12.1-q23 24990733 76110993 51.12 8.00E-06 30 5
19p13.3 8275 236875 0.23 8.00E-06 36.7 11.7
22p13-p11 134684 14797037 14.66 0.00964 21.7 5
22q13.1 37689087 37715408 0.03 8.00E-06 25 18.3
The Thresholds for losses of a single copy and homozygous deletions are set adaptively by the RAE method,
aMb: mega base pair.
doi:10.1371/journal.pone.0017250.t002
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FGF3, FGF4, PPF1A1, CTTN) and 7p12 (EGFR) by I-FISH.
Results were found to be concordant in 70% and 75% of the
samples (Figure S4).
Comparison of the identified copy number alterations to
published data. We compared the intervals found by RAE
(Table S2) to the locations of genes previously suggested in other
oral cancer studies. The genes overlapping with each interval are
shown in the column ‘OSCC genes’ in Table S2. The functional
role of representative candidate genes is discussed.
Discussion
In this study, we characterized genome-wide alterations in
locally advanced, tobacco-associated OSCC to identify markers of
poor prognosis for OSCC risk stratification. To our knowledge,
this is the first study of OSCC aCGH profiling from the Indian
subcontinent. Previous CGH studies of OSCC revealed gains of
8q followed by 3q, 9q, 11q13, 14q, and 20q and losses of 3p
followed by 4q, 5q, 8p, 9p, 10q, 11q, 18q, and 21q as the most
frequent alterations [7–13]. Our study not only validated the
previous reports but also revealed novel focal alterations previously
not described in oral cancers. Using aCGH, we observed focal
gains on chromosomal regions 3q27.1, 5p15.33, 14q11.2 and
19p13.3 and losses on 3p25.2–p26.3 and 9p23-p24.3 (PTPRD),
which were not reported previously in genome-wide studies of
OSCC. The focal alteration of 3q27.1 spans various proto-
oncogenes including ABCC5, ALG3, EIF4G1 and EPHB3.W e
identified a frequently altered small region on 5p15.33 spanning
twenty-four potential oncogenes. These genes, however, do not
include TERT and TRIO that have been proposed in the
literature. One of the new candidate gene on this locus is PDCD6
which has been shown to contribute towards tumor development
and expansion [27].
In our study cohort chromosomal arm 3p has been frequently
lost, which is consistent with previous reports. We observed a novel
Table 3. Genome-wide alterations in OSCC: Gains & Amplifications.
Cytoband Position Size (Mba) q value % Frequency
Start End Gains Amplifications
1q31.3 195026732 195104236 0.08 1.04E-05 35.0 28.3
1q31.3 195026732 195048237 0.02 1.04E-05 35.0 28.3
2q37.3 242501268 242717042 0.22 1.81E-05 33.3 21.7
3q13.33-q24 121355348 144551988 23.20 0.001810 21.7 1.7
3q27.1 185019156 185896384 0.88 1.04E-05 48.3 1.7
3q24-q29 145187343 199379595 54.19 1.04E-05 60.0 20.0
4q13.2 69085413 69165843 0.08 1.04E-05 35.0 26.7
5p15.33-p11 75178 46136094 46.06 1.04E-05 50.0 20.0
5p15.33 75178 942987 0.87 1.04E-05 48.3 18.3
6p21.33-p21.32 31524806 32225578 0.70 0.014905 21.7 3.3
6p21.32 32519964 32673012 0.15 4.59E-05 30.0 18.3
7p22.3-p11.1 149297 57562112 57.41 1.04E-05 50.0 20.0
8q24.13-q24.3 123102996 146250794 23.15 1.04E-05 71.7 10.0
8q11.1-q24.4 43452765 146250794 102.80 1.04E-05 73.3 13.3
9p24.3-p21.3 153160 21931457 21.78 1.04E-05 33.3 10.0
9p21.3-p13.1 21980551 39244358 17.26 1.81E-05 38.3 6.7
9q13-q34.3 70238468 140241905 70.00 1.04E-05 40.0 11.7
11q12.2-q14.2 60970713 78077527 17.11 1.04E-05 53.3 26.7
11q13.2-q13.3 68654476 70150073 1.50 1.04E-05 46.7 26.7
11q22.1-q22.2 101407278 102165885 0.76 0.021750 20.0 10.0
14q11.2 19560721 22142166 2.58 1.04E-05 46.7 5.0
14q11.2 21538460 22005864 0.47 1.04E-05 45.0 5.0
14q21.3-q31.1 48265939 80627188 32.36 0.000386 28.3 3.3
14q31.3-q32.33 87604117 106349785 18.75 9.60E-05 38.3 20.0
15q11.2 18741744 20060090 1.32 1.04E-05 35.0 13.3
17q25.3 77385789 78462808 1.08 1.04E-05 28.3 15.0
19p13.3 232109 258746 0.03 1.04E-05 58.3 31.7
20p13-p12.3 18609 5869816 5.85 0.022988 23.3 0.0
20p11.21 24728423 25680524 0.95 0.025337 20.0 0.0
20q11.21-q13.33 29436566 62363603 32.93 1.04E-05 40.0 8.3
The thresholds for gains of a single copy and amplifications by two or more copies were set adaptively by the RAE method.
aMb: mega base pair.
doi:10.1371/journal.pone.0017250.t003
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E3 ligase which is reported to play an important role in
homologous recombination and repairs double strand break
(dsb)[28]. We speculate that loss of RAD18 may lead to the
impaired DNA repair and genomic instability. Our study also
reports loss of PTPRG on 3p14.2. PTPRG encodes receptor-type
tyrosine-protein phosphatase gamma acting in growth control by
suppressing cyclin D1. A tumor suppressive function of PTPRG has
been reported in breast cancer [29] and PTPRG was one of the
earliest suggested oral cancer genes [30] but has not been reported
as lost in recent CGH studies. A related member, tyrosine-protein
phosphatase delta (PTPRD), present on chromosome 9p23-p24.3,
was suggested to be gained by Snijders et al. [7], but was not
selected as a driver gene for oral cancer. PTPRD is a known tumor
suppressor for lung cancer [31] and glioblastoma [32]. It
antagonizes growth stimulating signaling pathways that are also
altered in oral cancers. In our cohort, PTPRD had a complex
pattern of gains and losses; PTPRD was present in a small interval
that was lost in 23% of the cases (Table S2), but also in a larger
interval of 9p that was gained in 33% of the cases (Table S2). Due
to its anti-proliferative function we hypothesize that tumors with
PTPRD loss may be amenable to therapeutic intervention using
growth factor inhibitors.
HPV-related OSCCs are characterized by 16q loss and better
clinical outcome. Whereas HPV-unrelated tumors, such as those
studied here, had gains of 11q13 and more losses at 3p, 5q, 9p,
15q, and 18q with poor clinical outcome [18]. Array CGH
revealed that the samples in this study exhibit a genome-wide
Figure 2. Array CGH based identification of 9p23-p24.1 loss encompassing putative tumor suppressor gene PTPRD.
doi:10.1371/journal.pone.0017250.g002
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specimens from other parts of the world, substantiating the
presence of a distinct genomic profile of HPV-free OSCCs.
Most OSCC patients report with locally advanced disease at the
time of diagnosis (www.seer.cancer.gov/statfacts/html/oralcav.
html#survival). The overall survival of these patients is generally
poor as the majority of patients develop recurrent disease with
chemo- and/or radio-resistance. Patients at similar stages of
OSCC, however, do not have identical course of disease and often
differ in their clinical outcome. Hence, we analyzed advanced-
stage OSCC samples to delineate the genomic alterations that
could identify subsets of tumors differing with respect to
recurrence and survival. We note that the gain of chromosomal
region 11q22.1–q22.2 (P=0.009), losses of 17p13.3 (P=0.003)
and 11q23–q25 (P=0.0001) are associated with poor clinical
outcome. These regions were also found to be significantly
associated with recurrence-free survival (P=0.004, P=0.003, and
P=0.0003, respectively). Although the association of these
chromosomal loci with poor clinical outcome is novel, the loci
have been previously reported altered in OSCC [7,8,33]. In our
study, clinical outcome was strongly associated with specific
genomic aberrations detected by aCGH, however, there was no
significant association with clinicopathological markers such as
nodal status, grade or stage. This finding emphasizes the usefulness
of genomic alterations as independent markers of prognosis.
Amplification of 11q13 is reported in about 45% of HNSCC
[34,35]. We find the amplification in 47% of OSCC samples,
similar to the earlier reports. The amplification of the 11q13
region was validated using locus-specific FISH. Contradictory
reports exist on the association of 11q13 alterations with clinical
outcome [36–38]. We did not find any significant association of
11q13 with clinicopathological parameters or survival. In the
breakage-fusion-bridge (BFB) cycle model of 11q13 amplification,
distal 11q loss precedes 11q13 amplification and is therefore
considered an early event in HNSCC progression [39]. Jin et al.
reported that, in addition to 11q13 amplification, loss of distal 11q
may be important for biological aggressiveness of head and neck
carcinomas [40]. Further, they found that tumors with 11q loss
had concomitant 11q13 amplification. In our cohort only one case
(1.7%) had loss of distal 11q without the presence of 11q13 gain
(Table S3).
Loss of chromosomal region 11q23-25 was significantly
associated with poor clinical outcome. The results so obtained
were confirmed by I-FISH. Parikh et al. reported the loss of distal
region of 11q in HNSCC cell lines encompassing several DNA
damage response encoding genes (MRE11, ATM, H2AFX) and
found that this leads to compromised DNA damage response and
reduced sensitivity to ionizing radiation [33]. Henson et al.
reported a decreased expression of microRNAs miR-125b and
miR-100 present on distal 11q in OSCC cell lines and showed
their role in the development and progression of disease [41].
These microRNAs were regulated in a copy number dependent
fashion as well as via decreased expression of ATM [41]. Parikh et
al. predicted direct translational relevance for HNSCC patients, as
patients with distal 11q loss did not benefit from aggressive
radiation therapy [33]. Since in our study tumors with distal 11q
loss were found to be a subset of tumors with 11q13 gain, we
hypothesize that the distal 11q loss may be used as a risk marker to
identify patients who do not benefit from aggressive radiation
therapy, but could alternatively benefit from CCND1 inhibitors.
Another predictor of poor survival is the gain of 11q22.1–q22.2.
Snijders et al. reported the presence of this rare amplicon in 5.6%
of OSCC cases [7]. YAP1, BIRC2 and MMP7 genes present in this
region were proposed as the candidate driver genes based on their
role in apoptosis, cell adhesion and migration; BIRC3 was also
mentioned, but not identified as a driver gene. Baldwin et al.
reported the copy number gain of 11q22.2–q22.3 amplicon at a
higher frequency (15%) and identified two gene clusters with nine
matrix metalloproteinase (MMP) genes and two baculoviral IAP
repeat-containing protein (BIRC) genes [8]. In our study, the
11q22.1–q22.2 amplicon encompassing TRPC6, ANGPTL5 and
YAP1 was associated with poor clinical outcome. The frequency of
this alteration was 20%, similar to the frequency reported by
Baldwin et al. [8].
YAP1 can itself promote proliferation and transformation or it
can act as a transcriptional cofactor by regulating the expression of
Table 4. Univariate Cox proportional hazards regression analysis of single predictors for recurrence-free and overall survival.
Cytoband Aberration Recurrence-free survival Disease-specific survival
BH Corrected p-value* CPH coef. BH Corrected p-value* CPH coef.
3p25.3-p26.3 Loss .0.1 - 0.08 0.79
4q13.2 Loss .0.1 - 0.05 20.55
6p25.3 Loss 0.09 0.52 0.07 0.55
11q12.2-q14.1 Gain 0.06 0.46 0.06 0.48
11q22.1-q22.2 Gain 0.004 0.87 0.009 0.80
11q22.2-q22.3 Loss 0.005 1.25 0.001 1.46
11q23.1-q23.3 Loss 0.004 1.35 0.001 1.51
11q23.3-q25 Loss 0.0003 1.60 0.0001 1.76
11q25 Loss 0.001 1.46 0.0004 1.62
17p13.3 Loss 0.003 1.06 0.003 1.08
18p11.1-p11.21 Loss 0.09 0.78 0.04 0.93
19p13.3 Gain 0.06 20.51 0.04 20.59
20q11.21-q13.33 Gain 0.07 0.57 .0.1 -
*Benjamini-Hochberg [49] method of adjusting for multiple tests.
CPH coef.: Cox Proportional Hazard coefficient.
doi:10.1371/journal.pone.0017250.t004
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p53BP2 and the TEA domain (TEAD) transcription factor family
members [42]. YAP1 can induce anchorage-independent growth,
epithelial mesenchymal transition, growth factor-independent
proliferation, inhibit apoptosis and activate AKT and ERK
pathways [43]. Another candidate gene on 11q22 is TRPC6,a s
suggested by two recent studies which reported overexpression of
TRPC6 in glioma and glioblastoma multiforme (GBM) and
analyzed its functional importance in cell growth, proliferation
and increased radioresistance [44,45]. Although the relevance of
TRPC6 function in OSCC needs to be further explored, our data
indicate that TRPC6 may be one of the key genes responsible for
radioresistance and poor clinical outcome in OSCC.
We report chromosomal loss of 17p13.3 in 13% of oral cancer
samples analyzed. No previous study of oral cancer has identified
the loss of this locus. Losses of 17p13.3 have been reported in
many solid tumors including lung cancers [46]. The only known
gene in the precise region chr17:118,535–134,424 is RPH3AL, but
there exists no conclusive evidence for a tumor suppressive role
[47,48] despite the fact that loss of 17p13.3 is strongly associated
with poor recurrence-free and disease-specific survival.
In summary, our study reports genome-wide alterations in
tobacco-associated, HPV-unrelated oral cancers. The study
revealed genomic lesions on chromosome arms 11q and 17p13.3
associated with a high risk of relapse and decreased survival. These
genomic alterations can potentially help in risk stratification of oral
cancer patients beyond the currently used clinical paradigms. Our
findings demonstrate the use of genetic alterations for predicting
disease outcome, which may be helpful in developing accurate and
objective markers for the prognosis of oral cancers.
Figure 3. Patient survival curves and FISH validation of 11q23-q25 loss. A) Kaplan-Meier survival estimates of patient groups with and
without loss of chromosome 11q23–q25; survival in months (x-axis) is plotted against the fraction of samples alive (y-axis). Interphase FISH analysis
detecting the chromosome 11 centromere (red) and the 11q24.1 region (green), B) A case without 11q24.1 loss and C) A case of 11q24.1 loss are shown.
doi:10.1371/journal.pone.0017250.g003
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Figure S1 Screening of HPV DNA in tumor samples.
Representative gel picture of HPV general primer pair (GP5+/6+)
PCR. Beta-globin PCR was done to check the genomic integrity in
oral cancer samples. CaSki (HPV-16) and HeLa (HPV-18) cervical
cell lines were used as positive controls, while C-33A and SCC074
(HPV negative) cervical and oral cell lines were used as negative
controls. M: 50 bp marker.
(TIF)
Figure S2 Manhattan plot for statistically significant
genomic alterations in OSCC. The false discovery rates
(q-value; y-axis) for gains (blue) and losses (red) are plotted against
the 22 autosomes (x-axis). The threshold for significance (q#0.1) is
indicated by a dotted line. Stars (*) indicate known copy-number
variants (CNVs) according to the database of genomic variants
(DGV).
(TIF)
Figure S3 Metaphase FISH confirming the specificity of
BAC clones. A representative FISH image of metaphase plates
with A) FISH probes confirming the specificity of loci 11q22.1-
q22.2 (Green signals), B) 11q24.1 (Green signals) and chromosome
11 centromere (Panels A and B, Red signals).
(TIF)
Figure 4. Patient survival curves and FISH validation of 11q22.1-q22.2 gain. A) Kaplan-Meier survival estimates of patient groups with and
without gain of chromosome 11q22.1–q22.2; survival in months (x-axis) is plotted against the fraction of samples alive (y-axis). Interphase FISH
analysis detecting the chromosome 11 centromere (red) and the 11q22.1–q22.2 region (green), B) A case without 11q22.1-q22.2 gain and C) A case of
11q22.1–q22.2 gain are shown.
doi:10.1371/journal.pone.0017250.g004
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and 7p12 revealed by array CGH. A) Validation of 11q13.3
amplification by interphase FISH using centromere-specific (Cy3,
Red) and locus-specific (FITC, Green) probe. B) Validation of
7p12 amplification by interphase FISH using centromere-specific
(Cy3, Red) and locus-specific (FITC, Green) probe.
(TIF)
Table S1 Detailed demographic and clinicopathological data for
the study group.
(DOC)
Table S2 A compendium of chromosomal alterations in 60 oral
tumors with gene list and known candidate genes cited in the literature.
(XLS)
Table S3 Case-wise chromosomal aberrations at 11q in oral
cancer patients.
(DOC)
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